Conclusion
Alzheimer’s
We suggest a new avenue of clinical research to extend the effects of placebo personalisation to specific treatments, determine their mechanisms of action, and explore the optimisation of contextual factors in their delivery. Some interventions known to be susceptible to placebos (e.g. immunotherapy) may be more amenable to context optimisation than others (e.g., Alzheimer’s therapy; 